Do all cancers need to be treated? The role of thyroglobulin in the management of thyroid cancer. The 2006 Hayes Martin Lecture

Archives of Otolaryngology - Head and Neck Surgery

Volumn 133, Issue 7, 2007, Pages 639-643

  Heller, Keith S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN; THYROID HORMONE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONFERENCE PAPER; DRUG WITHDRAWAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MORTALITY; THYROID CANCER; THYROIDECTOMY;

DIAGNOSTIC IMAGING; HUMANS; NEOPLASM METASTASIS; PRACTICE GUIDELINES; RADIOTHERAPY, ADJUVANT; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 34447517279     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.133.7.639     Document Type: Conference Paper

References (25)

1. Quick D, Martin HE. The most common methods of gastrostomy with the report of a modified technique of the Janeway method. Surg Gynecol Obstet. March 1928;426-436.
2. Martin HE. Knot tying in surgery. Surg Gynecol Obstet. 1962;115(2):236-238.
3. O'Brien CJ. The parotid gland as a metastatic basin for cutaneous cancer. Arch Otolaryngol Head Neck Surg. 2005;131(7):551-555.
4. Myers EN, Gastman BR. Neck dissection: an operation in evolution: Hayes Martin Lecture. Arch Otolaryngol Head Neck Surg. 2003;129(1):14-25.
5. Attie JN. Hayes Martin Lecture: the physician (ARZT) and the arts. Am J Surg. 1996;172(6):618-624.
6. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130.
7. National Cancer Institute Surveillance Epidemiology and End Results. SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. www .seer.cancer.gov. Accessed April 29, 2006.
8. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid: a "normal" finding in Finland: a systematic autopsy study. Cancer. 1985;56(3):531-538.
9. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
10. Cooper DS, Doherty GM, Haugen BR, et al; The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-142.
11. Attie JN, Khafif RA, Steckler RM. Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg. 1971;122(4):464-471.
12. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):43-63.
13. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 1996; 18(2):127-132.
14. Colacchio TA, LoGerfo P, Colacchio DA, Feind C. Radioiodine total body scan versus serum thyroglobulin levels in follow-up of patients with thyroid cancer. Surgery. 1982;91(1):42-45.
15. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84(11):3877-3885.
16. 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med. 2001;42(10):1470-1475.
17. Wartofsky L; rhTSH Stimulated Thyroglobulin Study Group. Management of lowrisk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid. 2002;12(7):583-590.
18. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. 2002;87(4):1490-1498.
19. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002;12(1):37-43.
20. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87(4):1499-1501.
21. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433-1441.
22. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(8):3668-3673.
23. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89(7):3402-3407.
24. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83(12):2634-2648.
25. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26(8):879-885.